SLC7A11

Cystine/glutamate transporter

Score: 0.618 Price: $0.62 Medium Druggability Status: active Wiki: SLC7A11

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

815

DEBATES

3D Protein Structure

🧬 SLC7A11 — PDB 7EPF Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.55

Clinical Stage

Approved

Target Class

Transporter

Safety

0.50

Druggability Analysis

Drug Development0.75

Structural Tractability0.70

Target Class0.70

Safety Profile0.50

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Druggability Rationale: SLC7A11 demonstrates medium druggability (0.55) supported by existing approved drug (sulfasalazine) and robust structural data (4 PDB structures, cryo-EM, AlphaFold), confirming ligand-binding capability. However, transporter inhibition requires achieving selective blockade of cystine/glutamate exchange without disrupting other critical SLC7A-family functions, and achieving blood-brain barrier penetration remains challenging for neurodegenerative applications.

Mechanism: Small molecule inhibition of cystine/glutamate exchange

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Known Drugs:

Sulfasalazine (approved) — inflammatory bowel disease

Erastin (preclinical) — cancer research

Structural Data:

PDB (4) ✓AlphaFold ✓Cryo-EM ✓

7CCS 7EPZ 7P9U 7P9V

UniProt: Q9UPY5

🧬 3D Protein Structure

🧬 SLC7A11 — PDB 7EPF Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

SLC7A11 selectivity is achievable given its unique heterodimerization requirement with 4F2hc; however, off-target effects on related SLC7A family members (SLC7A1, SLC7A2) must be evaluated. Species differences in transporter pharmacology and potential compensatory transporter activation present additional selectivity concerns in chronic dosing.